Literature DB >> 12611887

Regulation of the cyclin D3 promoter by E2F1.

Yihong Ma1, Jing Yuan, Mei Huang, Richard Jove, W Douglas Cress.   

Abstract

We have previously demonstrated that ectopic expression of E2F1 is sufficient to drive quiescent cells into S phase and that E2F1 expression can contribute to oncogenic transformation. Key target genes in this process include master regulators of the cell cycle, such as cyclin E, which regulates G(1) progression, and cyclin A, which is required for the initiation of DNA synthesis. In the present work, we present novel evidence that a second G(1) cyclin, cyclin D3, is also potently activated by E2F1. First, an estrogen receptor-E2F1 fusion protein (ER-E2F1) potently activates the endogenous cyclin D3 mRNA upon treatment with 4-hydroxytamoxifen, which induces nuclear accumulation of the otherwise cytosolic fusion protein. Furthermore, trans-activation of cyclin D3 by ER-E2F1 occurs even in the presence of the protein synthesis inhibitor cycloheximide and thus appears direct. Second, all of the growth-stimulatory members of the E2F family (E2F1, -2, and -3A) potently activate a cyclin D3 promoter reporter, whereas growth-restraining members of the family (E2F4, -5, and -6) have little effect. Third, recombinant E2F1 binds with high affinity to the cyclin D3 promoter in vitro. Fourth, chromatin immunoprecipitation assays demonstrate that endogenous E2F1 is associated with the cyclin D3 promoter in vivo. Finally, mapping experiments localize the essential E2F regulatory element of the cyclin D3 promoter to a noncanonical E2F site in the promoter between nucleotides -143 and -135 relative to the initiating methionine codon. We conclude that in addition to cyclins E and A, E2F family members can also activate one member of the D-type cyclins, further contributing to the ability of the stimulatory E2F family members to drive cellular proliferation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12611887     DOI: 10.1074/jbc.M212702200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  Identification of cyclin D3 as a direct target of E2A using DamID.

Authors:  Siyuan Song; Jonathan Cooperman; Danielle L Letting; Gerd A Blobel; John Kim Choi
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

2.  MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation.

Authors:  Chuangui Wang; Alexey Ivanov; Lihong Chen; William J Fredericks; Ed Seto; Frank J Rauscher; Jiandong Chen
Journal:  EMBO J       Date:  2005-08-18       Impact factor: 11.598

3.  Activation of silenced tumor suppressor genes in prostate cancer cells by a novel energy restriction-mimetic agent.

Authors:  Hsiang-Yu Lin; Yi-Chiu Kuo; Yu-I Weng; I-Lu Lai; Tim H-M Huang; Shuan-Pei Lin; Dau-Ming Niu; Ching-Shih Chen
Journal:  Prostate       Date:  2012-04-26       Impact factor: 4.104

4.  Transcriptional upregulation of p57 (Kip2) by the cyclin-dependent kinase inhibitor BMS-387032 is E2F dependent and serves as a negative feedback loop limiting cytotoxicity.

Authors:  Y Ma; W D Cress
Journal:  Oncogene       Date:  2006-12-18       Impact factor: 9.867

5.  CDKN1C negatively regulates RNA polymerase II C-terminal domain phosphorylation in an E2F1-dependent manner.

Authors:  Yihong Ma; Lu Chen; Gabriela M Wright; Smitha R Pillai; Srikumar P Chellappan; W Douglas Cress
Journal:  J Biol Chem       Date:  2010-01-27       Impact factor: 5.157

6.  NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.

Authors:  Cynthia X Ma; Feng Gao; Jingqin Luo; Donald W Northfelt; Matthew Goetz; Andres Forero; Jeremy Hoog; Michael Naughton; Foluso Ademuyiwa; Rama Suresh; Karen S Anderson; Julie Margenthaler; Rebecca Aft; Timothy Hobday; Timothy Moynihan; William Gillanders; Amy Cyr; Timothy J Eberlein; Tina Hieken; Helen Krontiras; Zhanfang Guo; Michelle V Lee; Nicholas C Spies; Zachary L Skidmore; Obi L Griffith; Malachi Griffith; Shana Thomas; Caroline Bumb; Kiran Vij; Cynthia Huang Bartlett; Maria Koehler; Hussam Al-Kateb; Souzan Sanati; Matthew J Ellis
Journal:  Clin Cancer Res       Date:  2017-03-07       Impact factor: 12.531

7.  Negative regulation of cyclin D3 expression by transcription factor c-Ets1 in umbilical cord hematopoietic cells.

Authors:  Fan-kai Meng; Han-ying Sun; Xi-you Tan; Chun-rui Li; Jian-feng Zhou; Wen-li Liu
Journal:  Acta Pharmacol Sin       Date:  2011-08-15       Impact factor: 6.150

8.  Cyclin D3 promotes pancreatic β-cell fitness and viability in a cell cycle-independent manner and is targeted in autoimmune diabetes.

Authors:  Noemí Alejandra Saavedra-Ávila; Upasana Sengupta; Begoña Sánchez; Ester Sala; Laura Haba; Thomas Stratmann; Joan Verdaguer; Dídac Mauricio; Belén Mezquita; Ana Belén Ropero; Ángel Nadal; Conchi Mora
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

9.  Tripartite motif containing 28 (Trim28) can regulate cell proliferation by bridging HDAC1/E2F interactions.

Authors:  Lu Chen; Dung-Tsa Chen; Courtney Kurtyka; Bhupendra Rawal; William J Fulp; Eric B Haura; W Douglas Cress
Journal:  J Biol Chem       Date:  2012-10-11       Impact factor: 5.157

10.  A small-molecule E2F inhibitor blocks growth in a melanoma culture model.

Authors:  Yihong Ma; Courtney A Kurtyka; Sandhya Boyapalle; Shen-Shu Sung; Harshani Lawrence; Wayne Guida; W Douglas Cress
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.